Sponsored by HighRes® Biosolutions
When designing automation platforms in the early drug discovery space, there is a balance present between scoping for current needs and being ready for non-certain future directions. Instrument technologies evolve rapidly, and incorporating new workflows onto existing automation is a critical option to minimize implementation time and capital budget.
With the deployment of acoustic ejection mass spectrometry (AEMS, or Echo® MS) technology at BMS, our strategy was clear that to maximize investment in and impact of the instrumentation, a high-throughput detection model would require integration on automation. With significant automation footprint in place after several site evolutions, an existing platform was upgraded to enable 24/7 processing. With this proven success, a second Echo® MS unit was integrated, doubling capacity to generate data from upstream HTS automation platforms performing the assays.
Above topics will be covered, along with continuing efforts to improve performance in areas such as error capture and data movement. This automated Echo® MS platform has been successfully deployed for label-free analysis of many critical early drug discovery assays such as activity-based screens, mechanistic studies, HTS, and HT-ADME. Examples demonstrating the excellent speed, data quality and robustness of the platform will be presented in the webinar.
o Designing automation that is future-flexible
o Integrating novel instrumentation onto automation
o Managing instrument integration lifecycle (driver development, error capture, data movement)
o Leveraging high-throughput mass spectrometry (HTMS) for label-free screening
o Research collaboration on novel technologies